BIRC5 and neoplasm: In the absence of a clearly defined pro-tumor role of cell surface survivin, anti-survivin immunotherapies lack therapeutically relevant mechanisms, and their effects would be no different from those achieved by targeting any other surface antigen under similar conditions.